Known Medicine said it is building the world's largest purpose-built 3-dimensional cell culture dataset with millions of images of patient cancer cells responding to hundreds of drugs and combinations.
Their machine learning-based analysis relies on high-content images of these 3D micro-tumors to better understand why cells respond to one treatment over another.
Functional outcomes are combined with high dimensional -omics datasets to identify the best patients for existing drugs, and the best new drug candidates.
Their ability to capture patient-to-patient variability allows us to narrow the drug discovery funnel to identify a best-in-class molecule.
Additionally, they were recently recognized by VentureBeat, who named Known Medicine as the recipient of their AI Innovators award. This award spotlights a startup that holds great promise for making an impact with its AI innovation.
The BioTech Breakthrough Awards program aims to perform the most comprehensive evaluation of life sciences and biotechnology tools, services and companies TODAY, with nominations coming in from the best and brightest biotechnology innovators around the world.
All award nominations are fully analyzed, evaluated and scored by our expert panel of judges, representing a mix of technical, business, academic and marketing expertise within the industry. The evaluation criteria for the BioTech Breakthrough Awards program are focused around the concept of innovation.
Based in Salt Lake City, UT, Known Medicine is building a predictive engine that captures patient-to-patient variability to develop the best drug for every cancer.
Known Medicine merges cancer biology and machine learning to understand drug efficacy and patient-specific predictors of response.
By understanding how and why a patient responds to which therapy, Known Medicine said it is able to develop effective drug treatments with a high likelihood of success, and discover new drugs as its engine grows.
Shuttle Pharmaceuticals signs research agreement with Georgetown University for SP-2-225 assessment
Transcenta Holding doses first subject in TST003 US phase one study
PharmaJet Partner Scancell Posts Positive Clinical Results from COVID-19 DNA Vaccine Study
Fusion Pharmaceuticals doses first patient in phase one study assessing [225Ac]-FPI-2059 (FPI-2059)
Phanes Therapeutics doses first patient in phase one PT886 clinical study
TFS HealthScience expands into Israel
Reveal Genomics Technology Enters the Liquid Biopsy Field in Oncology
Lantern Pharma Posts New Data and Development Focus for LP-100 with PARP Inhibitors
Teva and Natco Launch Additional Strengths for the Generic Version of Revlimid in the US
Lightship Meets with US FDA to Discuss Approaches in Oncology Clinical Trials
Telix Pharmaceuticals receives Illuccix approval from FDA for supplementary New Drug Application
Collis Named SVP and Head of Preclinical Development at Ajax Therapeutics